Mucous Membrane Pemphigoid: Gum Blistering Symptoms and Care

Understanding Mucous Membrane Pemphigoid and Oral Anatomy

Mucous membrane pemphigoid oral disease represents a rare, chronic autoimmune subepithelial blistering disorder that predominantly targets the mucous membranes of the body. In the oral cavity, the condition most frequently involves the gingiva (the gums), buccal mucosa (inner cheeks), and palate (roof of the mouth). The oral lining is structured with an outer layer called the stratified squamous epithelium, which is tethered firmly to the underlying connective tissue, termed the lamina propria. This vital structural bond is maintained by a microscopic interface known as the basement membrane zone.

In patients with mucous membrane pemphigoid, the immune system mistakenly manufactures autoantibodies that target structural proteins within this basement membrane zone. As these autoantibodies bind to their target antigens, inflammatory cascades are activated, causing the epithelial layer to detach cleanly from the underlying connective tissue. This specific level of separation leads to the formation of subepithelial bullae, which are deep, tense blisters beneath the mucosal surface. Because the roof of these blisters consists of the full thickness of the epithelium, they are structurally sturdier than intraepithelial blisters, yet they eventually rupture under the mechanical friction of chewing, speaking, and tooth brushing, leaving painful, raw erosions.

Aetiology and Autoimmune Mechanisms

The precise trigger that initiates mucous membrane pemphigoid remains the subject of ongoing biomedical investigation, but it is fundamentally classified as an organ-specific autoimmune disease. In susceptible individuals, the immune system produces pathogenic immunoglobulin G (IgG), immunoglobulin A (IgA), and complement component C3 directed against specific adhesion proteins. The primary antigenic targets include BP180 (also known as type XVII collagen), BP230, laminin 332 (formerly known as epiligrin), and alpha-6 beta-4 integrin. These proteins form hemidesmosomes, the molecular anchors that secure the epithelial cells to the underlying extracellular matrix.

While genetic predispositions linked to specific human leukocyte antigen (HLA) alleles such as HLA-DQB1*03:01 have been identified, external factors may occasionally precipitate or exacerbate the autoimmune response. Certain medications, viral infections, or local tissue trauma can potentially disrupt immune tolerance in genetically vulnerable people. The condition is not infectious and cannot be transmitted to others. It is more frequently diagnosed in older adults, typically presenting between the ages of 60 and 80, with a slight predilection for women, though it can occur in individuals of any background or gender.

Clinical Presentation and Gum Blistering Symptoms

The hallmark oral manifestation of mucous membrane pemphigoid is desquamative gingivitis, a clinical term describing fiery red, glazed, and intensely inflamed gums that bleed readily upon the slightest contact. Patients often report that their gums look like raw meat and feel extremely tender or burning. Intact blisters (bullae) may occasionally be observed on the attached gingiva, palate, or tongue, appearing as fluid-filled or blood-tinged raised vesicles. However, because the oral environment is subject to constant moisture and shear forces, these blisters frequently burst within hours, leaving irregular, shallow ulcers covered by a yellowish-white fibrinous slough.

A notable clinical sign during oral examination is Nikolsky's sign, where gentle tangential pressure or an air blast applied to clinically normal-appearing mucosa induces peeling, shearing, or blister formation. Beyond gingival changes, patients experience marked functional impairment, finding it painful to consume acidic, spicy, or crunchy foods. In regions such as South Asia, the use of paan (betel quid), gutka, and smokeless tobacco introduces severe chemical and physical irritation that significantly aggravates the fragile mucosal lining, compounding tissue ulceration and complicating clinical assessment.

Diagnostic Pathway and Differential Diagnosis

Accurate diagnosis of mucous membrane pemphigoid oral lesions requires a comprehensive clinical evaluation combined with specific laboratory investigations. Routine dental radiographs or cone-beam computed tomography (CBCT) are generally unremarkable regarding the soft-tissue disease itself, but they are essential to rule out underlying periodontal bone loss that might be accelerated by chronic gingival inflammation. The definitive diagnosis hinges upon tissue biopsy. Clinicians must obtain two separate tissue samples: one from the edge of an active lesion (perilesional tissue) for routine haematoxylin and eosin (H&E) light microscopy, and a second fresh perilesional specimen for direct immunofluorescence (DIF) microscopy.

Routine histopathology demonstrates subepithelial clefting with a clean separation of the epithelium from the lamina propria, accompanied by a variable chronic inflammatory infiltrate containing lymphocytes, histiocytes, and eosinophils. Direct immunofluorescence is the gold standard diagnostic test; it reveals continuous linear deposition of IgG, IgA, or C3 along the basement membrane zone. Indirect immunofluorescence (IIF) and enzyme-linked immunosorbent assays (ELISA) performed on patient serum can detect circulating anti-basement membrane antibodies, helping identify specific target antigens such as laminin 332.

The differential diagnosis is broad because desquamative gingivitis is a clinical presentation shared by several distinct disorders. The primary conditions to distinguish include oral lichen planus, pemphigus vulgaris, linear IgA disease, lupus erythematosus, and erythema multiforme. Unlike pemphigus vulgaris, which exhibits intraepithelial blistering (acantholysis) within the upper layers of the tissue due to antibodies against desmogleins, mucous membrane pemphigoid features subepithelial splitting. Differentiating these entities is critical because their long-term systemic risks, monitoring protocols, and pharmacological treatment regimens differ substantially.

Clinical Classification and Multidisciplinary Risk Stratification

Mucous membrane pemphigoid is not a uniform condition; it is stratified clinically into low-risk and high-risk categories based on the anatomical sites involved and the specific autoantibody profile. Low-risk disease is defined as inflammation and blistering restricted solely to the oral mucosa and the skin. While painful and disruptive to daily oral function, low-risk oral involvement carries no direct threat to vital organ systems or vision.

Conversely, high-risk mucous membrane pemphigoid involves scarring-prone sites such as the ocular conjunctiva, the larynx, the oesophagus, or the genital mucosa. Ocular involvement (cicatricial pemphigoid) is particularly serious; chronic subepithelial inflammation causes fibrosis, symblepharon (adhesion between the eyelid and the eyeball), trichiasis (inward-turning eyelashes), corneal scarring, and potential irreversible blindness. Anti-laminin 332 pemphigoid represents another high-risk subset that requires careful surveillance, as it has an established association with underlying solid organ malignancies. Consequently, every patient diagnosed with oral lesions must undergo a thorough multidisciplinary screening by an ophthalmologist, dermatologist, and otolaryngologist.

Evidence-Based Treatment Modalities and Systemic Therapies

The primary therapeutic goals in managing mucous membrane pemphigoid oral disease are to control mucosal inflammation, promote lesion healing, relieve pain, and halt progressive scarring or extra-oral spread. For low-risk disease confined strictly to the oral cavity, high-potency topical corticosteroids represent the first-line evidence-based approach. Medications such as clobetasol propionate (0.05%) or betamethasone dipropionate gel or ointment are applied directly to dried mucosal lesions, often utilising custom-fabricated soft dental trays to increase contact time with the gingiva. Topical calcineurin inhibitors, such as tacrolimus (0.1%) ointment, serve as effective secondary topical agents.

When oral disease is widespread, refractory to topical regimens, or classified as high-risk, systemic pharmacotherapy becomes mandatory. Systemic corticosteroids (such as prednisolone) are employed to achieve rapid disease control, though they are tapered as quickly as feasible to mitigate adverse effects like osteoporosis, hypertension, and glucose intolerance. To maintain long-term remission, steroid-sparing immunosuppressive agents are introduced. Dapsone is frequently effective in milder systemic cases, provided glucose-6-phosphate dehydrogenase (G6PD) deficiency is ruled out prior to initiation.

For severe, progressive, or recalcitrant disease, potent immunosuppressants such as mycophenolate mofetil, azathioprine, or methotrexate are prescribed under specialist medical supervision. In high-risk refractory cases, particularly those with ocular or laryngeal threats, biologic therapy with rituximab—a monoclonal antibody directed against CD20-positive B cells—has demonstrated high rates of clinical remission in mainstream dermatological and immunological clinical trials. Intravenous immunoglobulin (IVIg) remains a valuable adjunctive option for complex, non-responsive cases.

The Clinical Appointment and Biopsy Procedure: Step-by-Step

When attending a specialist oral medicine or oral and maxillofacial surgery clinic for suspected mucous membrane pemphigoid, the appointment begins with an exhaustive medical history and systematic clinical mapping of all oral and extra-oral surfaces. The clinician examines the attached gingiva, vestibules, palate, tongue, and throat, noting areas of erythema, erosion, or blister formation. If a diagnosis has not yet been confirmed, a diagnostic mucosal biopsy will be scheduled or performed during the same visit.

The biopsy procedure is straightforward and performed under local anaesthesia. After administering a small volume of local anaesthetic solution—injected carefully adjacent to, rather than directly into, the biopsy site to prevent tissue distortion—the clinician selects a site of perilesional tissue showing mild erythema alongside intact epithelium. A circular punch biopsy (typically 3 to 4 millimetres in diameter) or an elliptical scalpel incisional biopsy is gently harvested. Extreme care is taken to avoid shearing the delicate epithelial roof off the underlying connective tissue during tissue handling.

The harvested tissue is divided or taken as two distinct samples: one is placed in standard 10% neutral buffered formalin for light microscopy, and the other is placed in Michel's transport medium or saline for direct immunofluorescence testing. Haemostasis is achieved using direct pressure, silver nitrate cautery, or one to two fine, resorbable sutures. The entire clinical procedure typically lasts approximately thirty to forty-five minutes, after which the patient receives detailed verbal and written post-operative instructions.

Post-Biopsy Recovery and Daily Oral Hygiene Protocols

Post-biopsy recovery generally involves mild discomfort that can be managed effectively with simple over-the-counter analgesics such as paracetamol. Patients should expect the surgical site to feel tender for three to seven days, and they should avoid consuming very hot, sharp, or spicy foodstuffs that could disturb the healing clot or sutures. If non-resorbable sutures were placed, they are usually reviewed and removed within seven to ten days.

Maintaining meticulous oral hygiene is both critical and challenging for individuals with mucous membrane pemphigoid. Because brushing inflamed gums causes friction, pain, and bleeding, patients often neglect plaque control, which inadvertently worsens secondary gingival inflammation and accelerates periodontal disease. To break this cycle, patients are advised to use an ultra-soft surgical toothbrush, apply non-foaming toothpaste free of sodium lauryl sulphate (SLS), and rinse with alcohol-free chlorhexidine gluconate (0.12% or 0.2%) or warm saline solutions to reduce bacterial load without inducing chemical irritation.

Potential Complications and Long-Term Disease Management

The long-term complications of mucous membrane pemphigoid span both local oral deterioration and life-altering extra-oral sequelae. Locally, chronic gingival desquamation combined with compromised plaque removal can lead to accelerated gingival recession, loss of periodontal attachment, and eventual tooth mobility. Furthermore, prolonged use of topical or systemic corticosteroids increases the risk of secondary oral candidiasis (fungal infection), which presents as white wiping plaques or an intense burning sensation, necessitating periodic antifungal therapy like nystatin or fluconazole.

Extra-oral complications present the greatest morbidity. Undetected conjunctival involvement can progress silently to subconjunctival fibrosis, symblepharon, and permanent blindness, underscoring the absolute necessity of routine ophthalmological reviews even if eye symptoms are absent. In the Indian context and globally, lifestyle habits must be addressed; the use of paan, gutka, areca nut, and tobacco products creates chemical trauma that severely exacerbates mucosal erosions, masks malignant transformation, and must be completely ceased. Long-term management requires continuous shared care between dental specialists, dermatologists, and primary physicians to monitor drug toxicity, mucosal stability, and systemic remission.

Evidence and further reading

Mainstream clinical consensus on mucous membrane pemphigoid is anchored in collaborative guidelines published by international dermatological and oral medicine authorities. The British Association of Dermatologists, the European Academy of Dermatology and Venereology (EADV), and the International Pemphigus and Pemphigoid Foundation have established evidence-based protocols highlighting the indispensability of direct immunofluorescence for definitive diagnosis and the critical need for multidisciplinary risk stratification.

Extensive reviews in peer-reviewed journals, including the Journal of the American Academy of Dermatology, the British Dental Journal, the International Journal of Oral and Maxillofacial Surgery, and Cochrane Systematic Reviews, consistently emphasise that early therapeutic intervention prevents irreversible fibrotic complications. The literature underscores that topical corticosteroids remain the gold standard for mild, oral-predominant disease, while systemic immunosuppressants and targeted biologics like rituximab provide effective disease control for refractory and high-risk cases.